HT23
TBAJ-876 is a novel anti-tuberculosis (TB) compound in the diarylquinoline class, which is the same class as bedaquiline. In vitro studies have suggested that the M3 metabolite may be linked to safety events, but its clinical significance is still unclear. Previously, population PK models were developed separately based on PK data from single ascending dose (SAD) and multiple ascending dose (MAD) studies, but they were not linked. The developed model suggested the potential food interaction of parent drug and first pass absoption of M3.
This project aims to develop a joint population PK model that simultaneously characterizes TBAJ-876 and M3 . This will provide a better understanding of the PK profile of TBAJ-876 and the formation of M3, potentially useful for further research, for instance dose selection, study design with clinical trial simulation.
Furthermore, this project is a collaboration with the TB Alliance (https://www.tballiance.org/), a global non-profit organization dedicated to finding faster-acting and affordable TB drugs.
The project requires programming skills in R and NONMEM.
The work will be carried out in Uppsala, however in a research group, that offers an international environment. The working language, including supervision, will be English.
Does this project sounds like something for you? Apply here or contact the supervisor (see below) or Maria Kjellsson (maria.kjellsson@farmaci.uu.se) if you have additional questions. We look forward to your application!
Farmaceutisk vetenskap
Farmakometri
Beräkningsstudie
Uppsala University
Uppsala
Elin Svensson, Thanakorn Vongjarudech
elin.svensson@farmaci.uu.se; thanakorn.vongjarudech@farmaci.uu.se
Institutionen för farmaci
Masterprogram i läkemedelsmodellering
Degree Project in Pharmaceutical Modeling within Pharmacometrics 45 c - 3FB029
45hp
1